RENVELA

LOE Approaching

sevelamer carbonate

NDAORALTABLET
Approved
Oct 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
15

Mechanism of Action

non-absorbed phosphate-binding cross-linked polymer, free of metal and calcium. It contains multiple amines separated by one carbon from the polymer backbone. These amines exist in a protonated form in the intestine and interact with phosphate molecules through ionic and hydrogen bonding. By…

Clinical Trials (5)

NCT03001011Phase 3Completed

Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In China

Started Jun 2017
202 enrolled
Hyperphosphatemia
NCT02332811Phase 3Completed

An Open Label, Dose Titration Study of Sevelamer Carbonate Tablets & Powder in Hyperphosphatemic CKD Patients

Started Oct 2013
96 enrolled
Renal Failure Chronic
NCT02346890Phase 1Completed

A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722

Started Apr 2013
16 enrolled
Healthy
NCT01574326Phase 2Completed

An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease

Started May 2012
101 enrolled
HyperphosphatemiaChronic Kidney Disease
NCT01857024N/ACompleted

Post Authorisation Safety Study of Renvela® in Chronic Kidney Disease Patients Not on Dialysis With Hyperphosphataemia

Started Sep 2010
210 enrolled
HyperphosphataemiaChronic Kidney Disease